TH-PVP is a substitute cathinone derivative which has been selling as a designer drug. It was first identified by a forensic laboratory in Hungary in 2015, but has subsequently been in numerous other countries around the world including Spain, Belgium, Poland, Turkey and Brazil. Pharmacological studies in vitro showed it to inhibit reuptake and promote the release of monoamine neurotransmitters. With some selectivity for serotonin, but it fail to produce stimulant effects in animals. Has a pharmacological profile more comparable to that of sedating empathogens such as MDAI and 5-Methyl-MDA.
6-(2-Aminopropyl)tetralin (6-APT). Also sometimes call tetralinylaminopropane (TAP), is a drug of the amphetamine class. Which acts as a selective serotonin releasing agent (SSRA). It has IC50 values of 121 nM, 6,436 nM, and 3,371 nM for inhibiting the reuptake of serotonin, dopamine, and norepinephrine, respectively. Though it posses an appreciable in vitro profile. In animal drug discrimination studies it is not found to substitute for MMAI. Amphetamine and to only partially substitute for MBDB. This parallels Alexander Shulgin’s finding that EDMA (the 1,4-benzodioxine analogue of 6-APT) is inactive. Appears to indicate that the pharmacokinetics of both EDMA and 6-APT may not be favorable.
Order TH-PVP online
Naphthylaminopropane (PAL-287) is an experimental drug under investigation as of 2007 for the treatment of alcohol and stimulant addiction.
Naphthylisopropylamine acts as a non-neurotoxic releasing agent of serotonin, norepinephrine, and dopamine, with EC50 values of 3.4 nM, 11.1 nM, and 12.6 nM, respectively. It also has affinity for the 5-HT2A, 5-HT2B, and 5-HT2C receptors (EC50 values = 466 nM, 40 nM, and 2.3 nM, respectively), and acts as a full agonist at 5-HT2B and as a partial agonist at 5-HT2C, while its affinity for 5-HT2A is probably too low to be significant.
In animal studies, naphthylisopropylamine shows to reduce cocaine self-administration, yet producing relatively weak stimulant effects when administer alone. Being a (much) lesser stimulant than d-amphetamine for comparison.  Further research is now[when?] being conduct in primates to see if it will be a useful substitute for treating drug addiction in humans as well.
An important observation is that in behavioral studies, rodents would consistently self-administer selective norepinephrine and dopamine. Releasing agents such as d-amphetamine, yet compounds that also release serotonin like naphthylisopropylamine will not be self-administer
In addition to the drugs (acute) effects on self-administration. All of the available evidence suggests that the locomotor activation cause by the majority of dopamine releasers is also dampen when the drugs also cause serotonergic release.  In fact, PAL-287 causes no locomotor activation at all (although admittedly the tests were only after acute dosing).